Equifax Rallies 18% After Earnings. What the Data Shows Now.

Equifax has gained 18.4% over the past week, closing Monday at $176.54 after reporting Q3 results on October 20. The pre-earnings short squeeze and options pivot that ORTEX flagged before the print have now resolved. Three fresh data points describe what the positioning landscape looks like on the other side.

Retail Attention Spikes Post-Print

Wikipedia views and ORTEX stock page traffic for Equifax have reached 2.7 standard deviations above the company's own 90-day average as of October 21. That reading, from the Wikipedia views dataset, reflects a sharp jump in retail attention following the earnings release. This is attention, not a revenue indicator. It does mark an unusual level of public interest for a stock that typically draws institutional rather than retail focus.

Analysts Reframe Targets After the Move

The two analyst actions on October 21 split in opposite directions, and the direction matters. Needham's Kyle Peterson raised his target to $210 from $190, maintaining Buy. Stifel's Shlomo Rosenbaum cut his target to $217 from $235, also maintaining Buy. The consensus target now sits at $198.40. Against Monday's close of $176.54, that implies roughly 12% further upside, a narrower gap than the 22% implied before the rally.

Mizuho lowered its target to $185 from $210 on October 19, before the print. That target is now below the current price. Oppenheimer's downgrade to Perform on October 16 also sits below the current level, with no published target. Two of the most recent analyst views, by price, are already looking backwards.

Short Interest Settles at 4.3% of Float

Short interest stood at 4.3% of the free float as of October 20, essentially unchanged from the 4.2% level flagged before the print. The 31% weekly collapse in short interest reported pre-earnings has not reversed. Borrow remains cheap at 0.44%, and availability is exceptionally loose at 3,568%, meaning roughly 35 shares remain available in the lending pool for every one already borrowed. There is no sign of fresh short-side conviction building after the results.

The put/call ratio was 1.58 on October 20, recovering partially from the 1.45 pre-earnings low but still below the 20-day mean of 1.94. Options positioning remains more constructive than it was for most of the quarter.

Index Radar: A December Threshold to Watch

ORTEX's Index Rebalance Radar puts a 52% chance that EFX is added to the CRSP US Small index at the December 2026 Quarterly Review. The price that decides it is $179.86. The stock needs to close 1.9% above Monday's level to reach that line by the December 4 rank date. If added, trackers would need to buy approximately $330 million of stock, representing 1.2 days of normal volume. This is a forecast, not an announcement. The rank date is December 4, with a trade date of December 22.

The same review carries a 46% chance of a share count decrease in the CRSP US Large index, implying $61 million of selling, and a 50% chance of a share count decrease in CRSP US Mid, implying $201 million of selling.

• Stock close, Oct 20: $176.54, up 11.3% on the day, up 18.4% on the week
• Short interest % of free float: 4.3% (Oct 20), down roughly 28% over the past month
• Availability: 3,568%, loose borrow market, no fresh short pressure visible
• PCR: 1.58 on Oct 20 vs 20-day mean of 1.94
• Consensus price target: $198.40 (as of Oct 21)
• Key level to watch: $179.86, the CRSP US Small index entry threshold, with December 4 as rank date